Sernova Corp (DE:PSH0)

XETRA:PSH0

PSH0

Sernova

RESEARCH TOOLSreports

Want to see DE:PSH0 full AI Analyst Report?

Sernova (PSH0) Price & Analysis

2 Followers

PSH0 Stock Chart & Stats

€0.11

Market closed

€0.11

Day’s Range― - ―

52-Week Range€0.06 - €0.20

Previous CloseN/A

VolumeN/A

Average Volume (3M)4.46K

Market Cap

€35.59M

Enterprise Value€74.35M

Total Cash (Recent Filing)€576.22K

Total Debt (Recent Filing)€17.55M

Price to Earnings (P/E)―

Beta0.04

Next Earnings

Jun 12, 2026

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding347,726,350

10 Day Avg. Volume5,531

30 Day Avg. Volume4,462

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)-1.96

Price to Sales (P/S)0.00

P/FCF Ratio-4.51

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.02

Revenue Forecast (FY)€187.25K

Bulls Say, Bears Say

Bulls Say

Proprietary PlatformSernova’s Cell Pouch System is a proprietary implantable platform built to host therapeutic cells and sustain long-term function. As a platform play in regenerative medicine, it can create durable differentiation versus drugs if clinically validated, supporting recurring therapeutic value for chronic diseases.

Moderating Cash BurnTTM operating cash outflow decreased versus prior years, indicating management has cut near-term cash consumption. Sustained moderation in burn rate materially extends runway to reach clinical inflection points, reduces immediate refinancing pressure, and improves the odds of funding through milestone-driven financing.

Improving Loss TrendSmaller net losses in 2025 and TTM versus prior years suggest better cost control or operational progress. A continuing trend of reduced losses can preserve cash, lower future financing needs, and increase the company's ability to execute clinical programs before needing large dilutive raises.

Bears Say

Pre-revenueThe company remains pre-revenue with zero sales across annual periods and TTM, meaning all R&D and operations depend on external funding. Long-term viability hinges on clinical and regulatory success and the ability to convert the platform into commercial products, raising execution and financing risk.

Weak Balance SheetDeeply negative equity combined with a sharp increase in debt (~$17.5M TTM) creates elevated balance-sheet risk. This limits strategic flexibility, heightens refinancing and covenant risk, and increases the likelihood of future dilution or onerous financing terms if development timelines slip.

Negative Cash GenerationOperating and free cash flow remain materially negative with declining FCF growth, reflecting structural cash-generation shortfalls. Ongoing burn necessitates recurrent external capital, elevating dilution and execution risk and constraining the company’s ability to advance multiple programs or respond to setbacks.

Sernova News

Sernova Shareholders Approve Debt-Reducing Issuances and Re-elect Board at 2026 AGM

The latest announcement is out from Sernova ( ($TSE:SVA) ). Sernova Biotherapeutics reported that all management proposals were...

1M ago

Sernova Raises $2.1 Million in Private Placement to Advance Diabetes Program

Sernova ( ($TSE:SVA) ) has provided an update. Sernova Biotherapeutics has closed a non-brokered private placement, raising $2.1...

2M ago

Sernova Bolsters Balance Sheet With $7.1 Million Financing and Debt Retirement Plan

Sernova ( ($TSE:SVA) ) just unveiled an announcement. Sernova Biotherapeutics has announced a series of financing transactions totaling...

2M ago

Sernova Amends Warrants to Extend Terms and Cut Exercise Prices for Investors

Sernova ( ($TSE:SVA) ) has issued an announcement. Sernova Biotherapeutics plans to amend terms on a large portion...

3M ago

Sernova Biotherapeutics Advances Diabetes Treatment with New Funding

Sernova ( ($TSE:SVA) ) has shared an announcement. Sernova Biotherapeutics has successfully closed the first tranche of a...

6M ago

Sernova Biotherapeutics Strengthens Financial Position with Debt-to-Equity Conversion

Sernova ( ($TSE:SVA) ) has provided an announcement. Sernova Biotherapeutics announced a significant financial restructuring by converting approximately...

7M ago

Sernova Biotherapeutics Appoints John L. Brooks III as Board Chair to Advance Diabetes Cure

The latest announcement is out from Sernova ( ($TSE:SVA) ). Sernova Biotherapeutics has appointed John L. Brooks III...

8M ago

Sernova Biotherapeutics to Present at Global Investment Conference

Sernova ( ($TSE:SVA) ) has issued an update. Sernova Biotherapeutics announced its participation in the H.C. Wainwright 27th...

8M ago

Sernova and Eledon Collaborate on Potential Type 1 Diabetes Cure

The latest update is out from Sernova ( ($TSE:SVA) ). Sernova Biotherapeutics has announced a collaboration with Eledon...

10M ago

Promising Advancements and Strategic Partnerships Bolster Sernova’s Buy Rating for T1D Treatment

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Sernova today and set a price target of...

10M ago

PSH0 FAQ

What was Sernova Corp’s price range in the past 12 months?

Sernova Corp lowest stock price was €0.06 and its highest was €0.20 in the past 12 months.

What is Sernova Corp’s market cap?

Sernova Corp’s market cap is €35.59M.

When is Sernova Corp’s upcoming earnings report date?

Sernova Corp’s upcoming earnings report date is Jun 12, 2026 which is in 34 days.

How were Sernova Corp’s earnings last quarter?

Sernova Corp released its earnings results on Mar 13, 2026. The company reported -€0.006 earnings per share for the quarter, the consensus estimate of -€0.006 by €0.

Is Sernova Corp overvalued?

According to Wall Street analysts Sernova Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sernova Corp pay dividends?

Sernova Corp does not currently pay dividends.

What is Sernova Corp’s EPS estimate?

Sernova Corp’s EPS estimate is >-0.01.

How many shares outstanding does Sernova Corp have?

Sernova Corp has 347,726,350 shares outstanding.

What happened to Sernova Corp’s price movement after its last earnings report?

Sernova Corp reported an EPS of -€0.006 in its last earnings report, expectations of -€0.006. Following the earnings report the stock price went down -9.244%.

Which hedge fund is a major shareholder of Sernova Corp?

Currently, no hedge funds are holding shares in DE:PSH0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sernova Corp

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.